A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer (RASTEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00717938

Recruitment Status : Completed

First Posted : July 18, 2008

Last Update Posted : August 25, 2017

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Sanofi

Information provided by (Responsible Party):

Lund University Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	May 2017
Actual Study Completion Date :	May 2017

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ek L, Gezelius E, Bergman B, Bendahl PO, Anderson H, Sundberg J, Wallberg M, Falkmer U, Verma S, Belting M; Swedish Lung Cancer Study Group (SLUSG). Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann Oncol. 2018 Feb 1;29(2):398-404. doi: 10.1093/annonc/mdx716.

To Top